Alzheimer-kór: vizsgálatok itt: Görögország
12 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- Where
- Athens, Ioannina, Maroussi, Patras, Thessaloniki
- Életkor
- 55 év to 90 év
- People
- 426 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00 - No phaseTaking peopleInRAD Observational Study
- Where
- Athens, Thessaloniki
- Életkor
- 18 év and over
- People
- 50 000 worldwide
- Run by
- Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
See details and how to joinNCT07213700 - 3. fázisTaking peopleA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Where
- Athens, Chaïdári, Heraklion, Kifissia, Thessaloniki
- Életkor
- 55 év to 90 év
- People
- 406 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Where
- Alexandroupoli, Athens, Larissa, Thessaloniki
- Életkor
- 60 év to 85 év
- People
- 586 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00 - 3. fázisTaking peopleOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Heraklion
- Életkor
- 55 év to 90 év
- People
- 1000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00 - 3. fázisTaking peopleA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
- Where
- Athens, Heraklion, Marousi
- Életkor
- 55 év to 90 év
- People
- 500 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06126224 · EU 2023-504416-16-00 - 3. fázisTaking peopleA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Where
- Athens, Ioannina, Maroussi, Patras, Thessaloniki
- Életkor
- 55 év to 90 év
- People
- 650 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
- Where
- Athens, Maroussi, Patras, Thessaloniki
- Életkor
- 60 év to 85 év
- People
- 586 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00 - No phaseTaking peopleThe Effect of Combination of Mediterranean Diet and Oleocanthal in Patients With Mild Cognitive Impairment
- Where
- Thessaloniki
- Életkor
- 60 év to 85 év
- People
- 200
- Run by
- Aristotle University Of Thessaloniki
See details and how to joinNCT06705738 - No phaseCsak meghívásosDigitally-enhanced, Decentralized, Multi-omics Observational Cohort
- Where
- Corfu, Thessaloniki
- Életkor
- 45 év and over
- People
- 100 000 worldwide
- Run by
- Greece 2021 Committee
See details and how to joinNCT04701177 - No phaseTaking peopleImpact of a Multicomponent Exercise Program on Cognitive and Functional Outcomes in Patients With Mild Cognitive Impairment
- Where
- Pátrai
- Életkor
- 50 év and over
- People
- 45
- Run by
- University of Patras
See details and how to joinNCT07334392 - No phaseTaking peoplePositive Psychology for Early Cognitive Decline: Effects on Cognitive and Brain Function
- Where
- Thessaloniki
- People
- 128
- Run by
- Aristotle University Of Thessaloniki
See details and how to joinNCT07289061